Calmangafodipir (5 µmol/kg)

DRUG2 trials

Sponsors

Egetis Therapeutics

Conditions

Chemotherapy-induced Peripheral NeuropathyColorectal Cancer

Phase 3

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

TerminatedNCT03654729

Egetis TherapeuticsChemotherapy-induced Peripheral Neuropathy, Colorectal Cancer

Start: 2018-11-07End: 2020-08-31Updated: 2021-12-17

Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer

TerminatedNCT04034355

Egetis TherapeuticsChemotherapy-induced Peripheral Neuropathy, Colorectal Cancer

Start: 2019-01-07End: 2020-08-31Updated: 2022-01-26

Related Papers

Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)

JNCI Cancer Spectrum2022-10-2419 citations

The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Journal of Clinical Oncology2019-05-202 citations

The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).

Journal of Clinical Oncology2019-01-291 citations